Urgent collective action to meet the challenge of this pandemic crisis: a coronavirus related...
The Director-General of the World Health Organization (WHO), Tedros Adhanom Ghebreyesus, first described the present coronavirus (COVID-19) outbreak as a pandemic on the 11th...
Medicines price transparency: Ground still left to cover
Parts of this blog were previously published in the Lancet Regional Health Europe
Secret medicines prices are hotly debated as European health systems struggle to...
Are gene-editing therapies patentable? A WIPO side event investigates.
On 6 December, Knowledge Ecology International (KEI) organised an interesting panel on the patentability of new gene- and cell-based medical therapies, as a side...
Some Surprises in the European Commission’s New Intellectual Property Strategy
The European Commission's new intellectual property (IP) strategy is out and it holds a number of surprises for access to medicines. After restating the...
New reports offer evidence for extending the WTO Decision on TRIPS to Covid-19 therapeutics...
In February 2024, the 13th World Trade Organization (WTO) Ministerial Conference will take place. WTO Members are expected to decide whether to extend the...
Why The Request By Least Developed Countries For An Extension Of The Transitional Period...
On 24 February 2015 Bangladesh on behalf of the 34 Least Developed Country members (LDCs) of the World Trade Organization (WTO) submitted a request...
Dutch Minister of Health writes open letter to pharma, threatens to name and shame
"Dear Pharma," writes the Dutch Minister of Health, Bruno Bruins in an open letter in the daily newspaper the Volkskrant, "Last week two messages jumped...
Something is going terribly wrong with the EU Compulsory Licensing Regulation
This week the European Parliament will vote on amendments to the Commission’s proposed regulation of the European Parliament and the Council on compulsory licensing...
Brazil’s Federal Court Reviews Medicines Mailbox Patents
This week the media reported that the Brazilian federal court removed the patent protection for eculizumab, sold under the brand name Soliris by Alexion...
ML&P’s Comments to the Intergovernmental Negotiating Body (INB) on the Zero Draft of the...
These remarks were delivered on the occasion of the fourth meeting of the Intergovernmental Negotiating Body to draft and negotiate a WHO convention, agreement...